Abstract
Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening disease characterized by recurrent flares of widespread skin eruptions of neutrophilic aseptic pustules that occur with or without systemic inflammation. Therapeutic intervention is a major challenge; globally, there are no approved treatments for acute GPP flares and there is a lack of robust clinical evidence to guide GPP treatment. Rapid improvements in skin symptoms with a single intravenous dose of spesolimab, an anti-IL-36 receptor antibody, was shown in a prior Phase I study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
